To provide an update of the prevalence and incidence of axial spondyloarthritis in the general population and in patients with spondyloarthritis-related conditions, environmental risk factors for ankylosing spondylitis, progression from nonradiographic axial spondyloarthritis to ankylosing spondylitis, mortality, and risks for cardiovascular events in patients with ankylosing spondylitis.
INTRODUCTION
Axial spondyloarthritis (SpA) is an umbrella term encompassing a number of inflammatory spine conditions, including ankylosing spondylitis, nonradiographic axial SpA (nr-axSpA), SpA associated with inflammatory bowel disease (IBD), and undifferentiated SpA. Since the publication of the Assessment of SpondyloArthritis International Society (ASAS) classification criteria in 2009, several studies have investigated the prevalence and incidence of axial SpA in the general population and in patients with SpArelated conditions. We review studies of the progression of patients with nr-axSpA to ankylosing spondylitis. Environmental factors, particular early life events, have been investigated for potential influence on the risk of later development of ankylosing spondylitis. We review recent studies of mortality in ankylosing spondylitis, and examine evidence of the risk of cardiovascular events in these patients.
PREVALENCE AND INCIDENCE

Prevalence
Recent studies reported the prevalence of ankylosing spondylitis to range from 9 to 30 per 10 000 in the general population, depending on geographic area, study population or data source, case definition, and ascertainment methods (Table 1 ) [1] [2] [3] [4] [5] [6] [7] . Prevalences were higher in selected risk groups. For example, in a Canadian study, the prevalence of ankylosing spondylitis was three times higher in First Nations people, a group with a high prevalence of HLA-B27, than in non-First Nations people [2] . In a Scottish study, the prevalence was three times higher among patients identified from primary care providers than under the care of rheumatologists [3] .
Two studies of the prevalence of axial SpA expectedly reported higher prevalences than those
Incidence
The reported prevalence from these recent studies was substantially lower than what was previously known. Studies from the same geographic location with similar methodology would help inform whether the frequency of axial SpA has truly decreased over time. The incidence of ankylosing spondylitis in Olmsted County, Minnesota from 1935 to 1989 was estimated at 7.3 per 100 000. In
KEY POINTS
Recent epidemiology studies indicate a lower prevalence and incidence of axial spondyloarthritis.
Patients with ankylosing spondylitis have a slightly increased risk for mortality and a slightly increased risk for cardiovascular events, including vascular death.
Current data suggested that using diagnostic codes for ankylosing spondylitis in administrative health data has high positive predictive value to identify these patients. the same population, the incidence of ankylosing spondylitis was 3.1 per 100 000 (95% CI 2.5-3.8) in 1980-2009 [9] . The authors attributed the decrease to increases in the local ethnic minority population. Whether these demographic changes fully explain the decline in ankylosing spondylitis incidence is unclear.
Study methods
Prevalence estimates may be affected by the ascertainment methods used in a study. Some studies used a two-step method, with an initial screening questionnaire followed by physician evaluation of screen-positive individuals. This method enhances accuracy, but can be limited in the number of participants included. Alternatively, population-based medical record linkage systems ensure near-complete case ascertainment, but require substantial time and resources to establish. Increasingly, studies have used administrative data to identify cases with axial SpA or ankylosing spondylitis, which require validation of the diagnosis codes and search algorithms used to identify affected persons. Curtis et al. [6] investigated the prevalence of axial SpA and ankylosing spondylitis in Kaiser Permanente health plan members, and described the performance of this method. Among 5568 individuals with at least one ICD-9 diagnosis code for ankylosing spondylitis, 2295 individuals only had a single code by a primary care provider. Ankylosing spondylitis was confirmed in only 2% of this group. Among four different search strategies, having two ICD-9 diagnoses of 720.X by rheumatologists had the highest positive predictive value at 81%, but sensitivity was only 67%. Similarly, Dubreuil et al. [10] tested the validity of ankylosing spondylitis diagnosis codes in United Kingdom's The Health Improvement Network using the general practitioner's diagnosis as the gold standard. They reported a positive predictive value of 88.6% for the presence of two ankylosing spondylitis diagnostic codes separated by at least 7 days, and a positive predictive value of 85.7% for the presence of one ankylosing spondylitis diagnosis code in combination with a disease-modifying drug or biologic prescription.
Bioinformatics tools, such as natural language processing applied to electronic medical records, are being explored as a new tool to identify cases. Walsh et al. [11] reported the positive predictive values of these models for several SpA-related concepts, including sacroiliitis, spondy Ã and HLA-B27þ, which ranged from 91.1 to 97.2%. Further studies are needed in this area.
PREVALENCE IN PATIENTS WITH RELATED CONDITIONS
Several studies examined the prevalence of ankylosing spondylitis in patients with related conditions, which may inform ways to improve referral and early diagnosis. Turina et al. [12] examined 51 first-degree relatives of patients with HLA-B27-positive ankylosing spondylitis, and 33% fulfilled criteria for SpA. More specifically, 57% had back pain, 6% had low-grade sacroiliitis, and 20% had sacroiliac bone marrow edema on imaging. The authors concluded that a substantial proportion of seemingly healthy relatives of ankylosing spondylitis patients had features of SpA.
Deodhar et al. [13] reported the proportion of patients with axial SpA among 751 patients with chronic back pain and either HLA-B27 positivity, inflammatory back pain, or sacroiliitis on imaging in the United States. Of these, 348 fulfilled ASAS axial SpA criteria (238 with nr-axSpA and 108 with ankylosing spondylitis). The authors suggested among patients with chronic back pain with onset younger than 45 years, having one of these three SpA features was an effective way to identify those with possible axial SpA.
Thom et al. [14] examined the prevalence of inflammatory back pain and SpA in patients with psoriasis using data from 2009 to 2010 National Health and Nutrition Examination Survey (NHANES), and found higher frequencies of axial pain (31 versus 19%) and inflammatory back pain (9.0 versus 4.9%) in persons with psoriasis than in those without psoriasis. The prevalence of SpA by Amor or European Spondyloarthropathy study group criteria was also significantly higher in the psoriasis group (14.3% versus 1.5%).
Chan et al. [15] reported the prevalence of sacroiliitis on computed tomography scans in patients with Crohn's disease, ulcerative colitis and controls as 15, 16.9 and 5.6%. Among 49 patients with IBD who had sacroiliitis on scans, only 5 had been seen by a rheumatologist. In a meta-analysis of 71 studies on the prevalence of axial SpA in patients with IBD, the pooled prevalence of sacroiliitis was 10%, although its prevalence in the subset of populationbased studies was only 3% [16 & ]. The pooled prevalence of ankylosing spondylitis was 3% overall, and 2% in population-based studies.
PROGRESSION OF NONRADIOGRAPHIC AXIAL SPONDYLOARTHRITIS
Since the development of axial SpA classification criteria, the relationship between nr-axSpA or undifferentiated SpA and ankylosing spondylitis has been of interest, particularly whether most patients with nr-axSpA progress to ankylosing spondylitis, and what are risk factors for progression.
We investigated these questions in a population-based study in Olmsted County, Minnesota [17 & ]. Among 83 patients who fulfilled ASAS criteria for axial SpA but did not have radiographic sacroiliitis, 19% progressed to ankylosing spondylitis after a mean follow-up of 10.6 years. The probability that the condition remained as nonradiographic at 5, 10, 15 years was 93.6, 82.7, and 73.6%. Patients who were classified through the imaging arm had a significantly more frequent and more rapid progression than those classified through the clinical arm (28 versus 17%, P ¼ 0.02).
Costantino et al. [18] reported a similar rate of progression in patients with axial SpA and having at least one SpA-affected relative. In 145 patients without radiographic sacroiliitis at inclusion, 27.3% developed radiographic sacroiliitis after 3-15 years, a result similar to our study. The Kaplan-Meier estimate of proportion of patients who progressed to radiographic sacroiliitis was 68.5% at 15 years of follow-up; however, in the analysis, patients who lost to follow-up were excluded from the number of patients at risk. Progression was associated with lowgrade radiographic sacroiliitis at baseline, buttock pain, and absence of peripheral arthritis.
Dougados et al. [19] examined radiographic progression over 2 years in the Devenir des Spondyloarthropathies Indiffererenciees Recentes (DESIR) cohort, a prospective cohort of patients with early inflammatory back pain and high suspicion for axial SpA. Sixteen of 326 patients (4.9%) with nr-ax SpA progressed to ankylosing spondylitis. This was quite different from the GESPIC cohort [20] , where 12% progressed to ankylosing spondylitis in 2 years. Current smoking, HLA-B27 positivity, and sacroiliac inflammation on imaging were the predictors for progression. In a follow-up study of the DESIR cohort, net progression from nr-axSpA to ankylosing spondylitis over 5 years was 5.1% [21] . Inflammation on baseline sacroiliac joint MRI predicted the presence of radiographic sacroiliitis at 5 years, both in HLA-B27-positive patients (OR 5.39; 95% CI 3.25-8.94) and in HLA-B27-negative patients (OR 2.16; 95% CI 1.04-4.51).
Xia et al. [22] conducted a systematic review and meta-analysis of 16 studies to assess the pooled rate of progression from undifferentiated SpA to ankylosing spondylitis. After 10 years, 40% of patients were projected to have progressed to ankylosing spondylitis.
Together, these findings suggest that only a small proportion of patients classified as nr-axSpA progress to ankylosing spondylitis, at least in the short-term.
ENVIRONMENTAL RISK FACTORS FOR THE DEVELOPMENT OF ANKYLOSING SPONDYLITIS
Ankylosing spondylitis is a highly heritable disease, and few studies have examined environmental risk factors. Three recent studies reported interesting observations suggesting that microbial exposures in childhood may play a role in the later development of ankylosing spondylitis.
Montoya et al. [23] investigated whether having been breast-fed was associated with the development of ankylosing spondylitis. Of 203 patients with ankylosing spondylitis, 57% were breast-fed, compared with 72% of 293 unaffected siblings, indicating that breast-feeding was protective (OR 0.53; 95% CI 0.36-0.77). The authors speculated that breast-feeding may have a protective effect on ankylosing spondylitis development in genetically susceptible patients by influencing the gut microbiota.
Lindström et al. [24] investigated whether childhood infections were associated with later development of ankylosing spondylitis in a case-control study in Sweden. Of the 2453 ankylosing spondylitis cases and 10 257 age-matched, sex-matched, and county-matched controls, 17.4% of cases and 16.3% of controls had an infection-related hospitalization before age 17 years. Ankylosing spondylitis was associated with slightly more respiratory tract infections (11.2 cases versus 9.2% controls) but few cases of appendicitis (1.5 versus 2.5%). The authors suggested early childhood infections might be associated with the subsequent development of ankylosing spondylitis. In a related analysis of potential maternal and puerperal risk factors, birth by Caesarean section was not associated with the risk of ankylosing spondylitis, but having at least one older sibling, a surrogate for exposure to infections, was associated with a slight increased risk of ankylosing spondylitis [25] .
MORTALITY AND CARDIOVASCULAR OUTCOMES
Mortality in ankylosing spondylitis
Recent information on mortality in ankylosing spondylitis is limited. Using the population-based Swedish National Patient Registry, Exarchou et al. [26] compared the mortality of persons with ankylosing spondylitis versus the general population. Over 7 years, they observed 496 deaths in 8600 patients with ankylosing spondylitis, compared with 1533 deaths in 40 460 matched controls, for a hazard ratio of 1.60 (95% CI 1.44-1.77). Less education, comorbidities, and history of hip replacement surgery were predictors of death.
In a population-based cohort study, Oza et al. [27 && ] examined the potential survival benefit of statin use in patients with ankylosing spondylitis. In a cohort of ankylosing spondylitis patients in a United Kingom general practice database, they compared mortality between matched cohorts of 1108 statin initiators and 1108 noninitiators using 1-year cohort accrual blocks. Over 5 years, the mortality rate was 16.5 per 1000 person-years among initiators and 23.8 per 1000 person-years among noninitiators (hazard ratio 0.63; 95% CI 0.46-0.85). The authors concluded that statin initiation was associated with a substantially lower risk of mortality in patients with ankylosing spondylitis.
Cardiovascular outcomes in ankylosing spondylitis
Studies on cardiovascular events in patients with ankylosing spondylitis have used different outcomes (Table 2 ) [28] [29] [30] [31] . Overall, results point to a small increase in cardiovascular event risk compared with general population.
In a population-based cohort study using administrative health data from Ontario, Canada, Haroon et al. [28] reported an adjusted hazard ratio for cardiovascular and cerebrovascular death in ankylosing spondylitis of 1.36 (95% CI 1.13-1.65), compared with matched nonankylosing spondylitis controls. Risk factors for vascular death included age, male sex, lower income, dementia, chronic kidney disease, peripheral vascular disease. Interestingly, among elderly patients with ankylosing spondylitis, use of nonselective nonsteroidal anti-inflammatory drugs and statins were protective for cardiovascular death.
In a population-based inception cohort of 86 patients with ankylosing spondylitis, Wright et al. [9] found a cumulative incidence of cardiovascular disease (including ischemic heart disease, myocardial infarction, angina, cardiovascular death, heart failure, peripheral arterial disease) of 15.8%, three times higher than the expected events predicted by the Framingham Risk Score. However, this study is limited by the small number of events. 
Epidemiology of axial spondyloarthritis Wang and Ward
Using Swedish population-based registries, Eriksson et al. [29] investigated the incidence of cardiovascular events in ankylosing spondylitis. Over 20 251 person-years of follow-up, the age and sex-adjusted relative risk for acute coronary syndromes was 1.3 (95% CI 1.0-1.7) compared with general population, and the relative risk for stroke was 1.5 (95% CI 1.2-1.8). Stroke risks were similarly elevated in ankylosing spondylitis and in patients with rheumatoid arthritis, whereas risks for acute coronary syndromes were only one-half as high in ankylosing spondylitis compared with rheumatoid arthritis.
Using claims data of Taiwan's National Health Insurance Research Database, Hung et al. [30] examined the incidence of cardiovascular disease (including hypertensive heart disease, coronary heart disease, congestive heart failure, cerebrovascular disease, and 'other') in an incident cohort of 437 patients with ankylosing spondylitis aged 40 years or older, compared with 2685 nonankylosing spondylitis patients. The hazard ratio for cardiovascular disease was 1.20 (95% CI 1.02-1.42). However, whenever isolating each condition, only the hazard ratio of 'other' cardiovascular disease was statistically significant.
In contrast, using British Clinical Practice Research Datalink, Essers et al. [31] identified 3809 incident ankylosing spondylitis patients from 1987 to 2012, who were each matched to seven nonankylosing spondylitis patients by age, sex, and practice. Risks were not significantly higher in ankylosing spondylitis, with an adjusted hazard ratio for ischemic heart disease of 1.20 (95% CI 0.97, 1.48) and for acute myocardial infarction of 0.91 (95% CI 0.65-1.28).
CONCLUSION
New information on the epidemiology of axial SpA includes a lower prevalence of axial SpA than previously reported, as well as a slightly increased risk for cardiovascular events and mortality. There has been an increase in studies using administrative and registry data to investigate these questions, for which sensitive and reliable methods are needed. On the basis of current data suggesting high predictive values of administrative healthcare codes for ankylosing spondylitis, use of these resources should be expanded. However, the lack of specific diagnostic codes means more work is needed before these methods can be used to study axial SpA in general.
